CRISPR Therapeutics AG (NASDAQ:CRSP) currently has a daily average trading volume of 1.12M but it saw 1596026 shares traded in last market. With a market cap of 4.43B USD, the company’s current market price of $51.88 came rising about 2.29 while comparing to the previous closing price of $50.72. In past 52 weeks, the stock remained buoying in the range of price level as high as $91.10 and as low as $43.42. In the recent trading on the day, stock has struck highest price mark of $51.145 while lowest mark touched by it was $53.26.
Taking a look at 20-day trading activity of CRISPR Therapeutics AG (CRSP) gives us an average price of $48.70, while its current price level is -43.05% below from 52-week high level whereas it is 19.48% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $47.37 while that of 200 days or SMA-200 reads an average of $57.92. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.04% during that period while stretching the period over a month that decreases to 4.05%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 62.19 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Needham which reiterated the stock as “Buy” in its note to investors issued on August 06, 2024, recommending a price target of between $88 and $84 for it.
Over the week, CRSP’s stock price is moving 11.83% up while it is 14.27% when we observe its performance for the past one month. Year-to-date it is -17.12% down and over the past year, the stock is showing a downside performance of -11.44%.
Currently, CRISPR Therapeutics AG’s total number of outstanding shares is 85.17M. Company’s return on investment (ROI) stands at -11.14% and return on equity (ROE) at -13.07%. Stock’s beta reads 1.62. Stock has a price to book (P/B) ratio of 2.28 while price to sale or P/S ratio amounts to 21.83. Its return on asset (ROA) is -11.03% on average.
